Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

Schoffski P.; Wozniak A.; Kasper B.; Aamdal S.; Leahy M. G.; Rutkowski P.; Bauer S.; Gelderblom H.; Italiano A.; Lindner L. H.; Hennig I.; Strauss S.; Zakotnik B.; Anthoney A.; Albiges L.; Blay J. -Y.; Reichardt P.; Sufliarsky J.; van der Graaf W. T. A.; Debiec-Rychter M.; Sciot R.; Van Cann T.; Marreaud S.; Raveloarivahy T.; Collette S.; Stacchiotti S.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

【24h】

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

机译：TFE3重排的肺泡软骨肉瘤患者中肝硬化患者的活性和安全性：欧洲癌症研究和治疗组织（EORTC）II期试验90101'Create'

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Alveolar soft part sarcoma (ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3 (TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the MET tyrosine kinase inhibitor crizotinib in patients with advanced or metastatic ASPS.

机译：肺泡软部分Sarcoma（ASPS）是与转录因子E3（TFE3）重新排列相关的孤儿恶性肿瘤，导致异常达到基因表达。我们预期评估了酪氨酸激酶抑制剂克里齐替尼在先进或转移性ASPs患者中的疗效和安全性。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology 》 |2018年第3期| 共8页
作者
Schoffski P.; Wozniak A.; Kasper B.; Aamdal S.; Leahy M. G.; Rutkowski P.; Bauer S.; Gelderblom H.; Italiano A.; Lindner L. H.; Hennig I.; Strauss S.; Zakotnik B.; Anthoney A.; Albiges L.; Blay J. -Y.; Reichardt P.; Sufliarsky J.; van der Graaf W. T. A.; Debiec-Rychter M.; Sciot R.; Van Cann T.; Marreaud S.; Raveloarivahy T.; Collette S.; Stacchiotti S.;
展开▼
作者单位

Univ Hosp Leuven Dept Gen Med Oncol Leuven Canc Inst Herestr 49 B-3000 Leuven Belgium;

Mannheim Univ Med Ctr Interdisciplinary Tumor Ctr Sarcoma Unit Mannheim Germany;

Oslo Univ Hosp Dept Oncol Oslo Norway;

Christie NHS Fdn Trust Manchester Lancs England;

Maria Sklodowska Curie Inst Ctr Oncol Dept Soft Tissue Bone Sarcoma &

Melanoma Warsaw Poland;

Univ Duisburg Essen Univ Hosp Dept Internal Med West German Canc Ctr Essen Germany;

Leiden Univ Med Ctr Dept Med Oncol Leiden Netherlands;

Inst Bergonie Sarcoma Unit Bordeaux France;

Univ Hosp Munich Med Clin 3 Munich Germany;

Nottingham Univ Hosp NHS Trust Dept Clin Oncol Nottingham England;

Univ Coll Hosp Dept Oncol London England;

Inst Oncol Dept Med Oncol Ljubljana Slovenia;

Leeds Teaching Hosp Natl Hlth Serv Trust St Jamess Univ Hosp Inst Oncol Leeds W Yorkshire;

Gustave Roussy Dept Med Oncol Villejuif France;

Ctr Leon Berard Dept Med Oncol Lyon France;

HELIOS Klinikum Berlin Buch Dept Interdisciplinary Oncol Berlin Germany;

Natl Canc Inst Bratislava Slovakia;

Radboud Univ Nijmegen Med Ctr Dept Med Oncol Nijmegen Netherlands;

Katholieke Univ Leuven Dept Human Genet Leuven Belgium;

Univ Hosp Leuven Leuven Belgium;

Univ Hosp Leuven Dept Gen Med Oncol Leuven Canc Inst Herestr 49 B-3000 Leuven Belgium;

European Org Res Treatment Canc Brussels Belgium;

European Org Res Treatment Canc Brussels Belgium;

European Org Res Treatment Canc Brussels Belgium;

IRCCS Fdn Ist Nazl Tumori Dept Med Oncol Milan Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词
alveolar soft part sarcoma; ASPS; transcription factor E3 (TFE3) gene rearrangement; MET expression; MET tyrosine kinase inhibitor; crizotinib;

机译：肺泡软部分肉瘤;ASP;转录因子E3（TFE3）基因重排;满足表达;达到酪氨酸激酶抑制剂;克里齐替尼;

相似文献

外文文献
中文文献

1. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE' [J] . Schoffski P., Wozniak A., Kasper B., Annals of oncology: official journal of the European Society for Medical Oncology . 2018 ,第3期

机译：TFE3重排的肺泡软骨肉瘤患者中肝硬化患者的活性和安全性：欧洲癌症研究和治疗组织（EORTC）II期试验90101'Create'
2. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE' [J] . Sch?ffski, Wozniak, Stacchiotti, Annals of oncology: official journal of the European Society for Medical Oncology . 2017 ,第12期

机译：高级清除细胞肉瘤患者的活动和安全性与达到改变的患者：欧洲研究和治疗癌症期二期试验90101'创造'
3. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE' [J] . Schoffski Patrick, Wozniak Agnieszka, Leahy Michael G., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018 ,第期

机译：酪氨酸激酶抑制剂Crozotinib在大量预处理的肺泡横纹肌肉瘤中没有临床有意义的活性，具有Foxo重排：欧洲研究和治疗癌症阶段的癌症组织2次试验90101'Create'
4. Nutritional Risk in the Cancer Patient 65 and Older Undergoing Systemic Treatment via Phase I Clinical Trials [D] . Williams, Anna Cathy. 2019

机译：癌症患者65岁及以上经受I期临床试验的营养风险
5. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ [O] . P Schöffski, A Wozniak, S Stacchiotti, -1

机译：克唑替尼在MET改变的晚期透明细胞肉瘤患者中的活性和安全性：欧洲癌症研究与治疗组织II期临床试验90101 CREATE
6. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ [O] . P. Schöffski, A. Wozniak, S. Stacchiotti, 2017

机译：具有符合符合符合变更的临床清除细胞肉瘤患者的活动和安全性：欧洲研究和治疗癌症期间试验90101'Create'的欧洲研究和治疗组织

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

摘要

著录项

相似文献

相关主题

期刊订阅